|
시장보고서
상품코드
2040866
심장병학용 AI 시장 규모, 점유율 및 동향 분석 보고서 : 구성 요소별, 용도별, 질환별, 지역별 및 부문별 예측(2026-2033년)AI In Cardiology Market Size, Share & Trends Analysis Report By Component (Software, Hardware, Services), By Application (Diagnosis, Prediction, Drug Discovery), By Medical Condition, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
심장병학용 AI 시장 요약
세계의 심장병학용 AI 시장 규모는 2025년에 16억 9,000만 달러로 추계되며, 2033년까지 148억 3,000만 달러에 달할 것으로 예측됩니다.
2026-2033년 CAGR 31.17%로 성장할 것으로 예상됩니다. 전 세계 심혈관 질환의 유병률 증가, 심장 전문의들의 진단 정확도 향상에 대한 관심 증가, 심장 영상 진단 기술의 급속한 발전 등이 심장학 분야에서 인공지능(AI)의 적용 확대를 견인하는 주요 요인으로 작용하고 있습니다.
예를 들어 2026년 1월, Cleerly, Inc.는 Aetna가 자사의 AI-QCT 플라크 분석 기술에 대한 보험 적용 범위를 확대했다고 발표했습니다. 이를 통해, AI를 활용한 관상동맥 이미징을 통한 관상동맥 질환 진단 및 위험도 평가 향상과 전체 피보험자 대상 임상 도입 확대가 가능해집니다.
심혈관 질환(CVD) 유병률 증가
심장학 분야에서 인공지능(AI)의 성장을 이끄는 주요 요인은 심혈관 질환(CVD)의 유병률 증가와 이에 따른 효율적이고 효과적인 헬스케어 솔루션에 대한 요구가 증가하고 있기 때문입니다. 세계보건기구(WHO)에 따르면 CVD는 여전히 전 세계 주요 사망 원인입니다. 예를 들어 2022년에는 약 1,980만 명이 CVD로 사망할 것으로 추정되며, 이는 전 세계 사망자의 약 32%를 차지합니다. 마찬가지로 미국 질병예방통제센터(CDC)에 따르면 2023년 미국에서 심혈관 질환으로 인해 91만 9,032명이 사망할 것으로 예상되며, 이는 전체 사망자 3명 중 1명이 심혈관 질환으로 사망할 것으로 예상됩니다. 이러한 부담 증가로 인해 질병 관리와 환자 예후를 개선하기 위한 첨단 기술의 개발 및 도입이 필수적입니다.
고혈압, 관상동맥질환, 심부전, 부정맥과 같은 질병의 높은 유병률은 전 세계 의료 시스템에 큰 부담을 주고 있습니다. 기존의 진단 및 치료법은 시간이 오래 걸리고 자원을 많이 소모할 뿐만 아니라 최적의 환자 치료에 필요한 정확도가 부족할 수 있습니다. AI는 CVD의 탐지, 진단, 관리의 정확성과 효율성을 높여 CVD의 변화를 가져올 수 있는 솔루션을 제공합니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 심장병학용 AI 시장 : 변수, 동향, 범위
제4장 심장병학용 AI 시장 : 컴포넌트별 추정·동향 분석
제5장 심장병학용 AI 시장 : 용도별 추정·동향 분석
제6장 심장병학용 AI 시장 : 질환 추정·동향 분석
제7장 심장병학용 AI 시장 : 지역별 추정·동향 분석
제8장 경쟁 구도
KSA 26.06.02AI In Cardiology Market Summary
The global AI in cardiology market size was estimated at USD 1.69 billion in 2025 and is projected to reach USD 14.83 billion by 2033, growing at a CAGR of 31.17% from 2026 to 2033. The rising global prevalence of cardiovascular diseases, coupled with the increasing focus of cardiac specialists on enhancing diagnostic precision and rapid advancements in cardiac imaging technology, are among the key factors responsible for expanding the applications of artificial intelligence (AI) in cardiology.
For instance, in January 2026, Cleerly, Inc. announced that Aetna expanded coverage for its AI-QCT plaque analysis technology, supporting improved diagnosis and risk assessment of coronary artery disease through advanced AI-enabled coronary imaging and broader clinical adoption across the insured population.
Increasing prevalence of cardiovascular diseases (CVDs)
A primary factor driving the growth of artificial intelligence (AI) in cardiology industry is the increasing prevalence of cardiovascular diseases (CVDs) and the consequent need for efficient & effective healthcare solutions. According to the WHO, CVD remains the leading cause of mortality worldwide. For instance, an estimated 19.8 million people died from CVDs in 2022, representing approximately 32% of all global deaths. Similarly, according to the Centers for Disease Control and Prevention (CDC), 919,032 people died from cardiovascular disease in the U.S. in 2023, equivalent to one in every three deaths. This escalating burden necessitates the development and implementation of advanced technologies to improve disease management and patient outcomes.
The high prevalence of conditions such as hypertension, coronary artery disease, heart failure, and arrhythmia puts a substantial strain on healthcare systems globally. Traditional diagnostic & treatment methods are often time-consuming & resource-intensive and are likely to lack the precision required for optimal patient care. AI offers a transformative solution by enhancing the accuracy and efficiency of CVD detection, diagnosis, and management.
Global AI In Cardiology Market Report Segmentation
This report forecasts revenue growth and provides at the global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global AI in cardiology market report based on component, application, medical condition, and region:
- Component Outlook (Revenue, USD Million, 2021 - 2033)
- Software
- Hardware
- Services
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Diagnosis
- Prediction
- Drug Discovery
- Others
- Medical Condition Outlook (Revenue, USD Million, 2021 - 2033)
- Cardiac Arrhythmias
- Heart Failure
- Ischemic Heart Disease /CAD
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Component Segment
- 1.2.2. Application Segment
- 1.2.3. Medical Condition Segment
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
Chapter 3. Artificial Intelligence in Cardiology Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Growing burden of cardiovascular diseases and the need for efficient healthcare solutions
- 3.2.1.2. Increasing strategic initiatives by industry players
- 3.2.1.3. Rapid technological advancements and growing adoption of remote patient monitoring solutions
- 3.2.2. Market restraint analysis
- 3.2.2.1. Highly regulated industry
- 3.2.2.2. High implementation and procurement costs
- 3.2.2.3. Shortage of healthcare personnel in information technology
- 3.2.3. Market opportunity analysis
- 3.2.4. Market challenges analysis
- 3.2.1. Market driver analysis
- 3.3. Case Study Insights
- 3.4. Artificial Intelligence in Cardiology Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's Five Forces Analysis
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
- 3.4.2.4. Environmental Landscape
- 3.4.2.5. Legal Landscape
- 3.4.2.6. Social Landscape
- 3.4.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Artificial Intelligence in Cardiology Market: Component Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Artificial Intelligence in Cardiology Market Component Movement Analysis
- 4.3. Global Artificial Intelligence in Cardiology Market Size & Trend Analysis, by Component, 2021 to 2033 (USD Million)
- 4.4. Software
- 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5. Hardware
- 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.6. Services
- 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Artificial Intelligence in Cardiology Market: Application Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Artificial Intelligence in Cardiology Market Application Movement Analysis
- 5.3. Global Artificial Intelligence in Cardiology Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 5.4. Diagnosis
- 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5. Prediction
- 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.6. Drug Discovery
- 5.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.7. Others
- 5.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Artificial Intelligence in Cardiology Market: Medical Condition Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Artificial Intelligence in Cardiology Market Medical Condition Movement Analysis
- 6.3. Global Artificial Intelligence in Cardiology Market Size & Trend Analysis, by Medical Condition, 2021 to 2033 (USD Million)
- 6.4. Cardiac Arrhythmias
- 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5. Heart Failure
- 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6. Ischemic Heart Disease /CAD
- 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7. Others
- 6.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Artificial Intelligence in Cardiology Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2025 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. U.S.
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework
- 7.4.1.3. Competitive scenario
- 7.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.2. Canada
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework
- 7.4.2.3. Competitive scenario
- 7.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.3. Mexico
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework
- 7.4.3.3. Competitive scenario
- 7.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.1. U.S.
- 7.5. Europe
- 7.5.1. UK
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework
- 7.5.1.3. Competitive scenario
- 7.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.2. Germany
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework
- 7.5.2.3. Competitive scenario
- 7.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.3. France
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework
- 7.5.3.3. Competitive scenario
- 7.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.4. Italy
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.5. Spain
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework
- 7.5.5.3. Competitive scenario
- 7.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.6. Norway
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework
- 7.5.6.3. Competitive scenario
- 7.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.7. Sweden
- 7.5.7.1. Key country dynamics
- 7.5.7.2. Regulatory framework
- 7.5.7.3. Competitive scenario
- 7.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.8. Denmark
- 7.5.8.1. Key country dynamics
- 7.5.8.2. Regulatory framework
- 7.5.8.3. Competitive scenario
- 7.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.1. UK
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework
- 7.6.1.3. Competitive scenario
- 7.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.2. China
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework
- 7.6.2.3. Competitive scenario
- 7.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.3. India
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Regulatory framework
- 7.6.3.3. Competitive scenario
- 7.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.4. Australia
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Regulatory framework
- 7.6.4.3. Competitive scenario
- 7.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Regulatory framework
- 7.6.5.3. Competitive scenario
- 7.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.6. Thailand
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Regulatory framework
- 7.6.6.3. Competitive scenario
- 7.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.1. Japan
- 7.7. Latin America
- 7.7.1. Brazil
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework
- 7.7.1.3. Competitive scenario
- 7.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7.2. Argentina
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework
- 7.7.2.3. Competitive scenario
- 7.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7.1. Brazil
- 7.8. MEA
- 7.8.1. South Africa
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Regulatory framework
- 7.8.1.3. Competitive scenario
- 7.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.2. Saudi Arabia
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Regulatory framework
- 7.8.2.3. Competitive scenario
- 7.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.3. UAE
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Regulatory framework
- 7.8.3.3. Competitive scenario
- 7.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.4. Kuwait
- 7.8.4.1. Key country dynamics
- 7.8.4.2. Regulatory framework
- 7.8.4.3. Competitive scenario
- 7.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.1. South Africa
Chapter 8. Competitive Landscape
- 8.1. Company/Competition Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Position Analysis, 2025
- 8.4. Company Profiles/Listing
- 8.4.1. GE Healthcare
- 8.4.1.1. Company overview
- 8.4.1.2. Financial performance
- 8.4.1.3. Technology type benchmarking
- 8.4.1.4. Strategic initiatives
- 8.4.2. Heartflow, Inc.
- 8.4.2.1. Company overview
- 8.4.2.2. Financial performance
- 8.4.2.3. Technology type benchmarking
- 8.4.2.4. Strategic initiatives
- 8.4.3. IDOVEN
- 8.4.3.1. Company overview
- 8.4.3.2. Financial performance
- 8.4.3.3. Technology type benchmarking
- 8.4.3.4. Strategic initiatives
- 8.4.4. CardiAI
- 8.4.4.1. Company overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Technology type benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. Ultromics Limited
- 8.4.5.1. Company overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Technology type benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. Arterys Inc. (Tempus AI)
- 8.4.6.1. Company overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Technology type benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. Ultrasight
- 8.4.7.1. Company overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Technology type benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. Koninklijke Philips N.V.
- 8.4.8.1. Company overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Technology type benchmarking
- 8.4.8.4. Strategic initiatives
- 8.4.9. Vista AI
- 8.4.9.1. Company overview
- 8.4.9.2. Financial performance
- 8.4.9.3. Technology type benchmarking
- 8.4.9.4. Strategic initiatives
- 8.4.10. Viz.ai, Inc.
- 8.4.10.1. Company overview
- 8.4.10.2. Financial performance
- 8.4.10.3. Technology type benchmarking
- 8.4.10.4. Strategic initiatives
- 8.4.11. RSIP Vision
- 8.4.11.1. Company overview
- 8.4.11.2. Financial performance
- 8.4.11.3. Technology type benchmarking
- 8.4.11.4. Strategic initiatives
- 8.4.12. Cleerly, Inc.
- 8.4.12.1. Company overview
- 8.4.12.2. Financial performance
- 8.4.12.3. Technology type benchmarking
- 8.4.12.4. Strategic initiatives
- 8.4.13. Medical AI Co., Ltd.
- 8.4.13.1. Company overview
- 8.4.13.2. Financial performance
- 8.4.13.3. Technology type benchmarking
- 8.4.13.4. Strategic initiatives
- 8.4.14. Anumana, Inc.
- 8.4.14.1. Company overview
- 8.4.14.2. Financial performance
- 8.4.14.3. Technology type benchmarking
- 8.4.14.4. Strategic initiatives
- 8.4.15. Aidoc
- 8.4.15.1. Company overview
- 8.4.15.2. Financial performance
- 8.4.15.3. Technology type benchmarking
- 8.4.15.4. Strategic initiatives
- 8.4.16. Circle Cardiovascular Imaging Inc.
- 8.4.16.1. Company overview
- 8.4.16.2. Financial performance
- 8.4.16.3. Technology type benchmarking
- 8.4.16.4. Strategic initiatives
- 8.4.17. Eko Health, Inc.
- 8.4.17.1. Company overview
- 8.4.17.2. Financial performance
- 8.4.17.3. Technology type benchmarking
- 8.4.17.4. Strategic initiatives
- 8.4.18. cardiomatics.com
- 8.4.18.1. Company overview
- 8.4.18.2. Financial performance
- 8.4.18.3. Technology type benchmarking
- 8.4.18.4. Strategic initiatives
- 8.4.1. GE Healthcare
